Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

311.29 +32.90 (+11.82%)
Official Closing Price Updated: 4:15 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,644,714
Open 313.39
Bid (Size) 311.40 (2)
Ask (Size) 311.95 (9)
Prev. Close 278.39
Today's Range 308.68 - 322.60
52wk Range 211.71 - 329.72
Shares Outstanding N/A
Dividend Yield 2.74%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dow Jones Industrial Average Gains 450 Points As Investors Up Rate Cut Bets After Softer NFP
The Dow Jones Industrial Average gained nearly 1.2% on Friday after a broad miss from US Nonfarm Payrolls) and other key labor data revealed a steep weakening in the US domestic economy, sparking... 
Via Talk Markets
Topics Economy Stocks
Exposures Economy US Equities
Why Amgen Stock Zoomed Nearly 12% Higher Today
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop. 
Via The Motley Fool

Performance

YTD
+4.67%
+4.67%
1 Month
+13.44%
+13.44%
3 Month
-3.68%
-3.68%
6 Month
+15.35%
+15.35%
1 Year
+34.24%
+34.24%

More News

Read More
Stocks Rally As Jobs Report Rekindles Rate Cut Hopes, Apple Rockets, Bitcoin Soars Above $61,000: What's Driving Markets Friday?
Via Benzinga
Amgen's Options: A Look at What the Big Money is Thinking
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
Amgen Outlook Is Bright, Analyst Predict Obesity-Focused Drug Potential Will Drive Shareholder Value
Via Benzinga
Topics Earnings
Exposures Financial
Why Is WideOpenWest (WOW) Stock Up 30% Today?
Via InvestorPlace
Wage Growth Slows – Stock Market Celebrates, Five Real Reasons Apple Is Running Up
Via Benzinga
AMGN Stock Alert: Is Amgen the Next Hot Weight-Loss Drug Company?
Via InvestorPlace
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
Via Benzinga
Wall Street Looks To Feed Off Apple's Post-Earnings Power But Key Jobs Data May Upset The Cart: Analyst Says 'A Lot Of These Clouds Will Lift' If This Happens
Via Benzinga
Why Apple Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate
Via Benzinga
Apple, Coinbase, Block, Amgen, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
Topics Stocks
Exposures US Equities
AMGN Stock Earnings: Amgen Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Via Benzinga
Amgen Beats First-Quarter Expectations, But Shares Slide As Investors Watch Obesity Space
Via Investor's Business Daily
Ticking Time Bombs: 3 Dow Stocks to Dump While You Still Can
Via InvestorPlace
Topics Stocks
Exposures US Equities
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With CytomX Stock?
Via Benzinga
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.